June 21, 2023 11:28 AM EDT

Trailing Akero and 89bio, Boston Pharmaceuticals posts early data on its NASH injection

Lei Lei Wu

News Reporter

In an early-stage study, Boston Pharmaceuticals’ injection reduced indicators of NASH, a fatty liver disease. The treatment is one of a handful of investigational drugs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Trailing Akero and 89bio, Boston Pharmaceuticals posts early data on its NASH injection

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Biotech VC firm outlines plans for $100M fund

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

FDA OKs the first-ever self-administered vaccine, for flu

Breaking down silos with a new quantitative approach to drug development

Trail­ing Akero and 89bio, Boston Phar­ma­ceu­ti­cals posts ear­ly da­ta on its NASH in­jec­tion

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Trailing Akero and 89bio, Boston Pharmaceuticals posts early data on its NASH injection